
23andMe bankruptcy filing sparks privacy fears as DNA data of millions goes up for sale
With genetic testing company 23andMe declaring bankruptcy and courting bidders, the DNA data of millions of users is up for sale.
A Silicon Valley stalwart since 2006, 23andMe has steadily amassed a database of people's fundamental genetic information under the promise of helping them understand their disposition to diseases and potentially connecting with relatives.
But the company's bankruptcy, declared Sunday, means that information is set to be sold, causing massive worry among privacy experts and advocates.
'Folks have absolutely no say in where their data is going to go,' said Tazin Kahn, CEO of the nonprofit Cyber Collective, which advocates for privacy rights and cybersecurity for marginalized people.
'How can we be so sure that the downstream impact of whoever purchases this data will not be catastrophic?' she said.
California Attorney General Rob Bonta issued a press statement Friday warning people that their data could be sold. In the statement, Bonta offered users instructions on how to delete genetic data from 23andMe, how to instruct the company to delete their test sample and how to revoke access from their data being used in third-party research studies.
DNA data is extraordinarily sensitive.
Its primary use at 23andMe — mapping out a person's potential predisposed genetic conditions — is data that many people would prefer to keep private. In some criminal cases, genetic testing data has been subpoenaed by police and used to help criminal investigations against people's relatives.
Security experts caution that if a bad actor can gain access to a person's biometric data like DNA information, there's no real remedy: Unlike a password or even address or Social Security number, a person cannot change their DNA.
A spokesperson for 23andMe told NBC News in an emailed statement that there will be no change to how the company stores customers' data, and that it plans to follow all relevant U.S. laws.
But Andrew Crawford, an attorney at the nonprofit Center for Democracy and Technology, said that genetic data lawfully acquired and held by a tech company has almost no federal regulation to begin with.
Not only does the U.S. not have a meaningful general digital privacy law, he said, but Americans' medical data faces less legal scrutiny if it's held by a tech company rather than by a medical professional.
The Health Insurance Portability and Accountability Act (HIPPA), which regulates some ways in which health data can be shared and stored in the U.S., largely only applies 'when that data is held by your doctor, your insurance company, folks kind of associated with the provision of health care,' Crawford said.
'HIPAA protections don't typically attach to entities that have IOT [internet of things] devices like fitness trackers, and in many cases the genetic testing companies like 23andMe,' he said.
There is precedent for 23andMe losing control of users' data.
In 2023, a hacker gained access to the data of what the company later admitted was around 6.9 million people, almost half of their user base at the time.
That led to posts on a dark web hacker forum, confirmed by NBC News as at least partially authentic, sharing a database that named and identified people with Ashkenazi Jewish heritage. The company subsequently said in a statement that protecting users' data remained 'a top priority,' and vowed to continue investing in protecting its systems and data.
Emily Tucker, the executive director of Georgetown Law's Center On Privacy & Technology, said that the sale of 23andMe should be a wake-up call for Americans about how easily their personal information can be bought and sold without their input.
'People must understand that, when they give their DNA to a corporation, they are putting their genetic privacy at the mercy of that company's internal data policies and practices, which the company can change at any time,' Tucker said in an emailed statement.
'This involves significant risks not only for the individual who submits their DNA, but for everyone to whom they are biologically related,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


NBC News
an hour ago
- NBC News
Palantir CEO Karp says AI is dangerous and 'either we win or China will win'
Palantir CEO Alex Karp said the artificial intelligence arms race between the U.S. and China will culminate in one country coming out on top. 'My general bias on AI is it is dangerous,' Karp told CNBC's ' Squawk on the Street ' on Thursday. 'There are positive and negative consequences, and either we win or China will win.' Karp has been a vocal advocate for U.S. AI dominance. He told CNBC in January that the country needs to 'run harder, run faster' in an 'all-country effort' to develop more advanced AI models. In a recent letter to shareholders, he also touted Palantir's commitment to equipping and enhancing U.S. defense interests. The billionaire tech CEO said Thursday that the U.S. currently has a leg up in the AI race and Palantir is leading the way in making companies more secure and efficient with its tools. 'There is no economy in the world with this kind of corporate leadership which is willing to pivot, which understands technologies, which is willing to look at new things, but also has deep domain expertise,' he said. 'Our allies in the West, in Europe, are going to have to learn from us.' Shares of the Denver-based data analytics and AI software firm outperformed in 2024 and have continued their ascent in 2025 as investors bet on their software and work with key government contractors and agencies. The stock is up 74% this year, but investors have to shell out on a higher earnings multiple than its tech peers. 'You don't like the price, exit,' Karp said Thursday in response. Karp also asserted that the company is 'not surveilling Americans' in response to recent New York Times report that Palantir is helping the Trump administration gather data on Americans.


NBC News
2 hours ago
- NBC News
'Whatever': Elon Musk responds to Trump's criticism of his opposition to GOP bill
Elon Musk took to social media to respond to President Trump's criticism of his opposition to the Republican's spending bill. NBC News' Kelly O'Donnell reports from the White House on how the relationship between the president and billionaire could be straining over the "Big, Beautiful Bill."


Metro
2 hours ago
- Metro
Donald Trump roasts Elon Musk and suggests he has 'Trump derangement syndrome'
President Donald Trump roasted Elon Musk for criticising his signature policy bill, suggesting that he has 'Trump derangement syndrome' and that he may no longer have a great relationship. Trump unleashed on Musk, claiming that he knew the bill better than almost anyone else in the administration and that he turned on it when it eliminated subsidies for electric vehicles. 'I think Elon misses this place. People leave my administration. And then at some point, they miss it so badly. And some of them actually become hostile,' said Trump in the Oval Office while meeting with German Chancellor Friedrich Merz on Thursday. 'It's sort of Trump Derangement Syndrome.' Got a story? Get in touch with our news team by emailing us at webnews@ Or you can submit your videos and pictures here. For more stories like this, check our news page. Follow on Twitter and Facebook for the latest news updates. You can now also get articles sent straight to your device. Sign up for our daily push alerts here. MORE: Donald Trump's travel ban isn't actually about protecting Americans MORE: Fears of a serial killer prowling Texas after 38 bodies pulled from lake in three years MORE: Ryanair passengers injured after storm throws 'people against cabin roof'